Piper Sandler on Abivax (ABVX): 'Obefazimod's Differentiated Profile Reinforced by UEGW Data'

October 21, 2026 8:45 AM

Piper Sandler analyst Allison M. Bratzel reiterated an Overweight rating and $175.00 price target on Abivax (NASDAQ: ABVX).The analyst commented ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found